Regulatory / Clinical Support
- Benefits of Regulatory Consulting
- Why Partner With NSF?
- Regulatory Services
NSF Pharma Biotech offers expert FDA regulatory/clinical support and consulting services to all sizes of pharmaceutical and biotech companies, investment firms, and regulatory or litigation counsel who need experts to interpret or navigate the intricacies of FDA pharmaceutical and biotechnology regulations.
We provide regulatory strategies, based on your corporate objectives, for product development, FDA approval pathways or lifecycle management of marketed pharmaceuticals and biologics. We also prepare or review relevant regulatory documentation, provide temporary regulatory affairs services or serve as the U.S. agent for pharmaceutical and biotechnology drug applications.
Our experts possess comprehensive knowledge of the regulatory requirements and a wealth of experience from agency interactions in developing numerous products. All efforts are directed by senior staff members with former leadership positions in both the FDA and industry, who have many years of experience interacting with the FDA and other regulatory agencies.
For more information about NSF Pharma Biotech regulatory/clinical support in the U.S., email email@example.com or call +1 202.822.1850.
For more information about NSF Pharma Biotech regulatory/clinical support in Europe, email firstname.lastname@example.org or call +44 1751 432 999.
Benefits of Regulatory Consulting
NSF provides your company:
- Widely recognized senior professionals with former leadership positions in both the FDA and industry
- Detailed knowledge of industry best practices that spans from early stage pre-clinical and clinical development to post-marketing approval
- Regulatory expertise across many product types: biologics (e.g. vaccines, recombinant proteins), small molecules, combination products, biosimilars, OTC and generic drugs
- Access to a broad network of global subject matter experts across many therapeutic areas
- An integrated approach that covers the complete product lifecycle from a regulatory and manufacturing (CMC) perspective
Why Partner With NSF?
NSF maintains a commitment to outstanding service and quality. We focus on achieving your business objectives through the use of sound science and proven expertise. NSF can assist across a wide range of therapeutic areas, product classifications and regulatory pathways. We are uniquely positioned to offer an integrated regulatory approach for your product’s development or product portfolio, with expertise in cGMP, ICH, GCP and regulatory requirements.
NSF provides regulatory solutions and strategic input across a wide variety of therapeutic areas. Our services include:
- Regulatory consultation for product development and regulatory strategy for new therapeutics and combination products, including assessment of applicability of unique programs and pathways available for approval (e.g. breakthrough therapeutics, orphan drug status eligibility for 505(b)(2))
- Due diligence assessments of early-stage startups for possible investment or established companies with a portfolio of approved drugs for possible acquisition/mergers
- Advice on product manufacturing and product specifications: review and preparation of chemistry, manufacturing and control programs
- Assistance with regulatory agency meeting interactions that includes preparing briefing documents, organizing meeting preparation sessions and leading FDA meetings. These include pre-IND, end-of-phase-2 (EOP2), pre-BLA, Type A, Type C and advisory committee meetings.
- Expertise in non-clinical study design and review
- Assistance in clinical protocol design and clinical trial support (e.g. CRO selection and contracting, IRB selection, drug management/labeling)
- Scientific review and medical writing support (e.g. investigator’s brochures, informed consents)
- In-house or Webex training on U.S. regulatory IND and NDA processes and approval pathways
- Review and preparation of Investigational New Drug (IND), New Drug Application (NDA), Biological Application License (BLA), Abbreviated New Drug Applications (ANDA) and lifecycle management submissions, such as Post Approval Supplements (PAS), all with eCTD format
- Interim regulatory affairs professionals to fill staffing shortages
- 3 days ago
Martin Lush, President, NSF Health Sciences Pharma Biotech, will be speaking at the 2014 PDA/FDA Pharmaceutical Quality System (ICH Q10)...
- 5 days ago
Janeen Skutnik-Wilkinson, Vice President, NSF Health Sciences Pharma Biotech will speak at The New Jersey Pharmaceutical Quality Control Association (NJPQCA)...
- 5 months ago
The long-awaited Qualified Persons template for declarations concerning Good Manufacturing Practice compliance of active substances and the accompanying guidance have...
- Monday, November 3, 2014
- 8:00am - 5:00pm
- Cambridge, Massachusetts, United States
- Monday, November 3, 2014
- 8:30am - 1:00pm
- Amsterdam, Netherlands
- Monday, November 10, 2014
- 8:30am - 5:00pm
- York, United Kingdom
- Tuesday, November 11, 2014
- 8:00am - 5:00pm
- Boston, Massachusetts, United States